Indian stocks: Visit www.stage2stocks.com →

Marker Therapeutics, Inc.

Stage 4 · Declining · week 13

As of Oct 22, 2026, Marker Therapeutics is in Stage 4, the downtrend phase, now in week 13 (since Jul 29, 2026). It closed at $1.07, 51.1% below its 52-week high and below its 200-day average, which is falling.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indication… More about the company

$1.07
-5.31% today
$17.8M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MRKR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 21w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 7w → S3 8w → S4 4w → S1 1w → S2 9w → S3 1w → S4 5w → S1 2w → S2 4w → S3 5w → S2 7w → S3 2w → S4 8w → S1 10w → S4 21w → S1 10w → S4 14w → S1 6w → S2 10w → S3 10w → S2 4w → S3 5w → S4 12w current
Total tracked: 165 weeks across 23 stage runs.

MRKR among Biotechnology177th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…177MRKRStage 4 · wk 1357−13.7%
vs 52W High
-51.1%
$0.86 lo$2.19 hi
51.1% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 13
1w13w26w
Week 13, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-23.4%
200 DMA: $1.40 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.79x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-13.7%
3M
-12.3%
6M
-26.2%
YTD
-30.5%
1Y
+2.9%
Scan Membership
Breakout Watch
Latest: 2024-07-08
9 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 13 · Vol 0.79x
2026-10-21S4
Wk 12 · Vol 1.27x
2026-10-20S4
Wk 12 · Vol 1.88x
2026-10-19S4
Wk 12 · Vol 5.76x
2026-10-16S4
Wk 12 · Vol 14.68x
2026-10-15S4
Wk 12 · Vol 1.55x
2026-10-14S4
Wk 11 · Vol 0.85x
2026-10-13S4
Wk 11 · Vol 2.34x
2026-10-12S4
Wk 11 · Vol 1.47x
2026-10-09S4
Wk 11 · Vol 1.25x
2026-10-08S4
Wk 11 · Vol 1.35x
2026-10-07S4
Wk 10 · Vol 0.52x
Moving averages & range
50 DMA
$1.17
200 DMA
$1.40
52W High
$2.19
52W Low
$0.86
5D Low
$1.04
Resistance levels (recent highs)
20d High
$1.20
60d High
$1.52
120d High
$1.68
250d High
$2.19
Next resistance
+12.1%
to 20d High
ROE
-76.9%
Profit margin -245.5%
Dividend Yield
0.00%
P/B 1.5

Marker Therapeutics: quick answers

What stage is Marker Therapeutics in?

As of Oct 22, 2026, Marker Therapeutics (MRKR) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 29, 2026 and is in week 13. What the four stages mean

Is Marker Therapeutics in an uptrend?

No. Marker Therapeutics is in a Stage 4 downtrend. It trades 23.4% below its 200-day average, which is falling.

How far is Marker Therapeutics from its 52-week high?

Marker Therapeutics closed at $1.07 on Oct 22, 2026, 51.1% below its 52-week high of $2.19. Its 52-week low is $0.86.

How has Marker Therapeutics performed over the past year?

As of Oct 22, 2026, Marker Therapeutics is up 2.9% over the past year and down 30.5% so far in 2026.

Which sector and industry is Marker Therapeutics in?

Marker Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.